KB-208

• Description:

  KB-208 is a phagocytosis inhibitor that acts similarly to intravenous immunoglobulin (IVIG) . KB-208 improves immune thrombocytopenia (ITP) in a mouse model at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum biochemical markers of toxicity, and can be used in research in the field of immunity[1][2].

• UNSPSC:

  12352005

• Target:

  Others

• Related Pathways:

  Others

• Field of Research:

  Inflammation/Immunology

• Concentration:

  10mM

• Purity:

  98.00

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(CC1CCN(CC1)C(C2=CC(C3=CC=CS3)=NN2C4=CC=CC=C4)=O)OC

• Molecular Formula:

  C22H23N3O3S

• Molecular Weight:

  409.50

• References & Citations:

  [1]Loriamini M, et al. A novel small molecule phagocytosis inhibitor, KB-208, ameliorates ITP in mouse models with similar efficacy as IVIG. Transfusion. 2024 Dec;64 (12) :2233-2240.|[2]Aşık A, et al. Amcasertib Increases Apoptosis While Decreasing Invasive and Migrating Abilities in Breast Cancer Stem Cells[J]. Clinical and Experimental Health Sciences, 2024, 14 (3) : 800-806.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1282128-68-0]